62 related articles for article (PubMed ID: 36940556)
1. Regorafenib induces NOX5-mediated endoplasmic reticulum stress and potentiates the anti-tumor activity of cisplatin in non-small cell lung cancer cells.
Sui H; Xiao S; Jiang S; Wu S; Lin H; Cheng L; Ye L; Zhao Q; Yu Y; Tao L; Kong FM; Huang X; Cui R
Neoplasia; 2023 May; 39():100897. PubMed ID: 36940556
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways.
Ni L; Zhu X; Zhao Q; Shen Y; Tao L; Zhang J; Lin H; Zhuge W; Cho YC; Cui R; Zhu W
Neoplasia; 2024 May; 51():100991. PubMed ID: 38507887
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells.
Yu Y; Wu T; Zhang X; Li P; Ye L; Kuang J; Tao L; Ni L; Zhao Q; Zhang J; Pan H; Xie C; Zheng C; Li S; Cui R
Eur J Pharmacol; 2023 Oct; 957():175986. PubMed ID: 37598924
[TBL] [Abstract][Full Text] [Related]
4. Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis.
D'Abrosca B; Ciaramella V; Graziani V; Papaccio F; Della Corte CM; Potenza N; Fiorentino A; Ciardiello F; Morgillo F
Sci Rep; 2019 Mar; 9(1):4986. PubMed ID: 30899059
[TBL] [Abstract][Full Text] [Related]
5. Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell Lung Cancer Cells.
Chen X; Zhang H; Pan Y; Zhu N; Zhou L; Chen G; Wang J
Appl Biochem Biotechnol; 2024 Jan; 196(1):182-202. PubMed ID: 37103738
[TBL] [Abstract][Full Text] [Related]
6. Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells.
Zhan Y; Chen Q; Song Y; Wei X; Zhao T; Chen B; Li C; Zhang W; Jiang Y; Tan Y; Du B; Xiao J; Wang K
Cell Biol Toxicol; 2023 Aug; 39(4):1297-1317. PubMed ID: 36070022
[TBL] [Abstract][Full Text] [Related]
7. Renal protective effect of polysulfide in cisplatin-induced nephrotoxicity.
Cao X; Nie X; Xiong S; Cao L; Wu Z; Moore PK; Bian JS
Redox Biol; 2018 May; 15():513-521. PubMed ID: 29413963
[TBL] [Abstract][Full Text] [Related]
8. Tannins in Phyllanthus emblica L. improves cisplatin efficacy in lung cancer cells by boosting endoplasmic reticulum stress to trigger immunogenic cell death.
Hu Q; Wang S; Cheng R; Liu Y; Chang Z; Huang Y; Chen Y; Luo X; Zhou L; Wang B; Gao Y; Chen H; Liu R; Zhang L
Phytomedicine; 2024 Jan; 123():155219. PubMed ID: 38056150
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-based combination therapy for cancer.
Minerva ; Bhat A; Verma S; Chander G; Jamwal RS; Sharma B; Bhat A; Katyal T; Kumar R; Shah R
J Cancer Res Ther; 2023; 19(3):530-536. PubMed ID: 37470570
[TBL] [Abstract][Full Text] [Related]
10. Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress.
Liu S; Yang P; Wang L; Zou X; Zhang D; Chen W; Hu C; Xiao D; Ren H; Zhang H; Cai S
Cell Death Discov; 2024 Jan; 10(1):36. PubMed ID: 38238316
[TBL] [Abstract][Full Text] [Related]
11. Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer.
Lucas A; Belcher DA; Munoz C; Williams AT; Palmer AF; Cabrales P
Oncotarget; 2020 Oct; 11(42):3770-3781. PubMed ID: 33144918
[TBL] [Abstract][Full Text] [Related]
12. Correction: XAF1 overexpression inhibits the malignant progression and cisplatin resistance of NSCLC by activating endoplasmic reticulum stress.
Chen B; Cheng Y; Wu H; Yao J
Mol Biol Rep; 2024 May; 51(1):699. PubMed ID: 38814432
[No Abstract] [Full Text] [Related]
13. Discussion to: An angiotensin system inhibitor (losartan) potentiates antitumor efficacy of cisplatin in a murine model of non-small cell lung cancer.
JTCVS Open; 2024 Apr; 18():322-323. PubMed ID: 38690417
[No Abstract] [Full Text] [Related]
14. Regorafenib-induced Myopathy.
Ochiai S; Ueno T; Igarashi S; Arai A
Intern Med; 2024 Jan; ():. PubMed ID: 38220194
[No Abstract] [Full Text] [Related]
15. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients.
Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J
Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099
[TBL] [Abstract][Full Text] [Related]
16. Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review.
Liu J; West H; McGee HM; Williams TM; Lee P; Amini A
Neoplasia; 2023 Sep; 43():100914. PubMed ID: 37348427
[TBL] [Abstract][Full Text] [Related]
17. Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma.
Jiang J; Xiang J; Chen M; Wan Y; Zhong L; Han X; Chen X; Wang J; Xiao F; Liu J; Li H; Huang H; Hou J
Cancer Sci; 2023 Jul; 114(7):2750-2760. PubMed ID: 37002866
[TBL] [Abstract][Full Text] [Related]
18. PI3K-CCL2-CCR2-MDSCs axis: A potential pathway for tumor Clostridia-promoted CD 8
Ma WJ; Li ZH; Wu ZR; Liu F; Wang JK; Shi YJ; Jin YW; Li FY
Neoplasia; 2023 Sep; 43():100920. PubMed ID: 37515847
[TBL] [Abstract][Full Text] [Related]
19. Low-Temperature Plasma-Activated Medium Inhibits the Migration of Non-Small Cell Lung Cancer Cells via the Wnt/
Zhang Y; Yan Z; Wu H; Yang X; Yang K; Song W
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509109
[TBL] [Abstract][Full Text] [Related]
20. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
